ANVS
| Market cap | $98.46M |
|---|---|
| Enterprise value | $229.18M |
| Revenue | $0.00 |
|---|---|
| EBITDA | N/A |
| Income | -$47.53 |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E | N/A |
|---|---|
| Forward P/E | N/A |
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| PEG | N/A |
| Price/Sales | N/A |
| P/FCF | N/A |
| Price/Book | -12.70 |
| Book/Share | -1.22 |
| Cash/Share | 0.90 |
| FCF yield | -35.93% |
| Volume | 0.000 / 604.558k |
|---|---|
| Relative vol. | 0.00 × |
| EPS | N/A |
|---|---|
| EPS Q/Q | 165.71% |
| Est. EPS Q/Q | 33.33% |
| Profit margin | 0.00% |
|---|---|
| Oper. margin | N/A |
| Gross margin | N/A |
| EBIT margin | N/A |
| EBITDA margin | N/A |
| Ret. on assets | -372.37% |
|---|---|
| Ret. on equity | -1,166.77% |
| ROIC | -243.15% |
| ROCE | -1,615.00% |
| Debt/Equity | -2.32 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.60 |
| Quick ratio | 1.60 |
| Volatility | 11.71% |
|---|---|
| Beta | N/A |
| RSI | 77.31 |
|---|
| Insider ownership | 30.94% |
|---|---|
| Inst. ownership | 15.14% |
| Shares outst. | 6.947M |
|---|---|
| Shares float | 5.518M 79.43% |
| Short % of float | 3.49% |
| Short ratio | 1.78 |
| Dividend | N/A |
|---|---|
| Dividend yield | N/A |
| Payout ratio | N/A |
| Payment date | N/A |
| Ex-dividend date | N/A |
| Earnings date | N/A |
Tuesday, 11 October 2022
|
|
| Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's Disease | |
Thursday, 6 October 2022
|
|
| Lab Notes: Venatorx lands federal contract that could be worth $318M; Annovis Bio receives FDA approval to proceed with trial | |
| Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's Disease | |
Tuesday, 13 September 2022
|
|
| Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases - Yahoo Finance | |
Thursday, 28 April 2022
|
|
| Annovis Bio Announces Cooperative Research and Development Agreement with the National Institute on Aging - Yahoo Finance | |
Tuesday, 8 March 2022
|
|
| Annovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022 - Yahoo Finance | |
Friday, 28 January 2022
|
|
| Lab Notes: AmerisourceBergen teams with UK tech firm; Chimeron Bio relocates to Center City | |
| Insider | Age | Since | Compensation |
|---|---|---|---|
| Dr. Maria L. MacCecchini Ph.D. (70) Founder, CEO, Pres, and Director | 70 | $420,000 | |
| Jeffrey B. McGroarty CPA (52) Chief Financial Officer | 52 | $300,000 | |
| Dr. William C. Mobley | |||
| Dr. Jeffrey L. Cummings CCF, M.D., ScD (72) Chief Medical Advisor and Member of Scientific Advisory Board | 72 |
Quarterly EPS estimates
Profit margin
Debt to assets
Cash flow
Balance sheet
XSLX
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Current assets | |||||
| Cash | $3.136968 | $5.75472 | |||
| Short term investments | |||||
| Net receivables | |||||
| Inventory | |||||
| Total current assets | $7.813295 | $10.208264 | |||
| Long term investments | |||||
| Property, plant & equipment | |||||
| Goodwill & intangible assets | |||||
| Total noncurrent assets | |||||
| Total investments | |||||
| Total assets | $7.813295 | $10.208264 | |||
| Current liabilities | |||||
| Accounts payable | $4.106832 | $1.292837 | |||
| Deferred revenue | |||||
| Short long term debt | |||||
| Total current liabilities | $4.870015 | $4.27911 | |||
| Long term debt | |||||
| Total noncurrent liabilities | $6.297308 | $13.68 | |||
| Total debt | |||||
| Total liabilities | $11.167323 | $17.95911 | |||
| Stockholders' equity | |||||
| Retained earnings | -$111.326034 | -$110.259087 | |||
| Other stockholder equity | |||||
| Total stockholder equity | -$3.354028 | -$7.750846 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Current assets | ||||
| Cash | $5.75472 | $28.377693 | ||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $10.208264 | $36.022069 | ||
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $10.208264 | $36.022069 | ||
| Current liabilities | ||||
| Accounts payable | $1.292837 | $3.961254 | ||
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $4.27911 | $7.698539 | ||
| Long term debt | ||||
| Total noncurrent liabilities | $13.68 | |||
| Total debt | ||||
| Total liabilities | $17.95911 | $7.698539 | ||
| Stockholders' equity | ||||
| Retained earnings | -$110.259087 | -$54.054774 | ||
| Other stockholder equity | ||||
| Total stockholder equity | -$7.750846 | $28.32353 | ||
Income statement
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Revenue | |||||
| Total revenue | |||||
| Cost of revenue | |||||
| Gross profit | |||||
| Operating activities | |||||
| Research & development | $6.51492 | $8.904729 | |||
| Selling, general & administrative | $1.294887 | $1.537595 | |||
| Total operating expenses | $7.809807 | $10.442324 | |||
| Operating income | -$7.809807 | -$10.442324 | |||
| Income from continuing operations | |||||
| EBIT | -$1.066947 | -$22.213394 | |||
| Income tax expense | |||||
| Interest expense | |||||
| Net income | |||||
| Net income | -$1.066947 | -$22.213394 | |||
| Income (for common shares) | -$1.066947 | -$22.213394 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross profit | ||||
| Operating activities | ||||
| Research & development | $38.790603 | $16.515543 | ||
| Selling, general & administrative | $6.244408 | $8.995736 | ||
| Total operating expenses | $45.035011 | $25.511279 | ||
| Operating income | -$45.035011 | -$25.511279 | ||
| Income from continuing operations | ||||
| EBIT | -$56.204313 | -$25.328567 | ||
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$56.204313 | -$25.328567 | ||
| Income (for common shares) | -$56.204313 | -$25.328567 | ||
Cash flows
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Net income | -$1.066947 | -$22.213394 | |||
| Operating activities | |||||
| Depreciation | |||||
| Business acquisitions & disposals | |||||
| Stock-based compensation | $0.364765 | $0.882384 | |||
| Total cash flows from operations | -$7.032752 | -$9.364976 | |||
| Investing activities | |||||
| Capital expenditures | |||||
| Investments | |||||
| Total cash flows from investing | |||||
| Financing activities | |||||
| Dividends paid | |||||
| Sale and purchase of stock | $4.415 | $8.764754 | |||
| Net borrowings | |||||
| Total cash flows from financing | $4.415 | $8.764754 | |||
| Effect of exchange rate | |||||
| Change in cash and equivalents | -$2.617752 | -$0.600222 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Net income | -$56.204313 | -$25.328567 | ||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $4.628406 | $9.15252 | ||
| Total cash flows from operations | -$39.967304 | -$17.312934 | ||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $17.344331 | $0.004613 | ||
| Net borrowings | ||||
| Total cash flows from financing | $17.344331 | $0.004613 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$22.622973 | -$17.308321 | ||
Sign up